# Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

> **NCT01415882** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 165 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Daratumumab
- **DRUG:** Dexamethasone
- **DRUG:** Ixazomib Citrate
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01415882
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-31
- **Primary completion:** 2023-04-21
- **Final completion:** 2025-04-30
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01415882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01415882, "Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01415882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*